Publisher
Springer Science and Business Media LLC
Reference10 articles.
1. Betts RF, Nucci M, Talwar D, et al.; Caspofungin High-Dose Study Group: A multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis. Clin Infect Dis 2009, 48:1676–1684.
2. Groll AH, Mickiene D, Petraitiene R, et al.: Pharmacokinetic and pharmacodynamic modeling of anidulafungin (LY303366): reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma sampling. Antimicrob Agents Chemother 2001, 45:2845–2855.
3. Maertens J, Raad I, Petrikkos G, et al.; Caspofungin Salvage Aspergillosis Study Group: Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 2004, 39:1563–1571.
4. Herbrecht R, Maertens J, Baila L, et al.: Caspofungin as first-line therapy of invasive aspergillosis in allogeneic hematopoietic stem cell transplant recipients: a study of the EORTC Infectious Diseases Group [abstract M2167]. Presented at the American Society for Microbiology 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC; October 25–27, 2008.
5. Labelle AJ, Micek ST, Roubinian N, Kollef MH: Treatment-related risk factors for hospital mortality in Candida bloodstream infections. Crit Care Med 2008, 36:2967–2972.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献